中基長壽科學(00767.HK)授出ZJ1 VC緩釋片和NMN系列產品代理權
中基長壽科學(00767.HK)公佈,附屬「浤烽」與連鎖藥房「榮華藥業」簽署銷售代理合約,浤烽授權榮華藥業爲浤烽所售營養補充劑ZJ1 VC緩釋片、NMN系列產品的代理商,成爲香港本地非獨家銷售商。對於浤烽後續推出產品和服務,浤烽將優先考慮授權榮華藥業爲代理商,並協商簽訂補充協定。
雙方合作期爲三年,自銷售代理合約簽署之日起開始計,雙方同意在自簽約之日起第一年內須完成2,000萬元的產品和服務消費,之後每年業績按照15%遞增。雙方合作開始,榮華藥業在銷售代理合約生效五個工作日內向浤烽支付1,000萬元採購產品及服務費用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.